The pathobiology of pediatric B-cell precursor acute lymphoblastic leukemia (Book, 2018) [WorldCat.org]
skip to content
The pathobiology of pediatric B-cell precursor acute lymphoblastic leukemia Preview this item
ClosePreview this item
Checking...

The pathobiology of pediatric B-cell precursor acute lymphoblastic leukemia

Author: Lieneke Steeghs
Publisher: Erasmus University Rotterdam 2018-07-04
Edition/Format: Book Book : English
Summary:
Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease, caused by the malignant transformation of either T-cell (~15% of the cases) or B-cell progenitors (~85% of the cases). To further improve the survival of children with ALL, new targeted treatment strategies are warranted. Therefore, it is essential to gain insight in the pathobiology of childhood ALL. The scope of this thesis is on pediatric  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Find a copy online

Links to this item

Find a copy in the library

We were unable to get information about libraries that hold this item.

Details

Document Type: Book
All Authors / Contributors: Lieneke Steeghs
ISBN: 978-94-92801-35-7
Language Note: English
Unique Identifier: 8086642739
Awards:

Abstract:

Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease, caused by the malignant transformation of either T-cell (~15% of the cases) or B-cell progenitors (~85% of the cases). To further improve the survival of children with ALL, new targeted treatment strategies are warranted. Therefore, it is essential to gain insight in the pathobiology of childhood ALL. The scope of this thesis is on pediatric B-cell precursor ALL (BCP-ALL). We studied: 1) the occurrence of tyrosine kinase fusion genes (i.e. ABL and JAK class) and JAK2 mutations in pediatric BCP-ALL cases; 2) the efficacy of JAK inhibitors in JAK2 aberrant (translocations and point mutations) leukemic cells; 3) the potential of STAP1 as therapeutic target for DUX4-rearranged ALL cases; 4) the association between copy number aberrations in B-cell development genes (e.g. IKZF1, PAX5), long‑term prognosis, and cellular drug resistance; 5) the supportive properties and gene expression profiles of mesenchymal stromal cells derived from pediatric BCP-ALL patients and healthy pediatric donors. Our results show efficacy of new precision medicines, i.e. JAK inhibitors, but we also identified important limitations that should be overcome. Moreover, we show that the genetic context matters and that the effect of anti-cancer drugs should be studied in the proper genetic context. Lastly, we show that mesenchymal stromal cells are not actively involved in BCP-ALL leukemogenesis. Instead leukemic cells actively modulate signaling pathways in MSCs to support BCP-ALL cell survival. Targeting this interaction between BCP‑ALL cells and MSCs might be an attractive alternative treatment strategy.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.